GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Novo Nordisk A/S (NYSE:NVO) » Definitions » Price-to-Owner-Earnings

Novo Nordisk A/S (Novo Nordisk A/S) Price-to-Owner-Earnings : 40.11 (As of May. 06, 2024)


View and export this data going back to 1981. Start your Free Trial

What is Novo Nordisk A/S Price-to-Owner-Earnings?

As of today (2024-05-06), Novo Nordisk A/S's share price is $123.13. Novo Nordisk A/S's Owner Earnings per Share (TTM) ended in Mar. 2024 was $3.07. It's Price-to-Owner-Earnings for today is 40.11.


The historical rank and industry rank for Novo Nordisk A/S's Price-to-Owner-Earnings or its related term are showing as below:

NVO' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 12.66   Med: 23.59   Max: 57.08
Current: 40.16

During the past 13 years, the highest Price-to-Owner-Earnings of Novo Nordisk A/S was 57.08. The lowest was 12.66. And the median was 23.59.


NVO's Price-to-Owner-Earnings is ranked worse than
57.93% of 164 companies
in the Biotechnology industry
Industry Median: 34.175 vs NVO: 40.16

As of today (2024-05-06), Novo Nordisk A/S's share price is $123.13. Novo Nordisk A/S's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was $2.89. Therefore, Novo Nordisk A/S's PE Ratio for today is 42.61.

As of today (2024-05-06), Novo Nordisk A/S's share price is $123.13. Novo Nordisk A/S's EPS without NRI for the trailing twelve months (TTM) ended in was $2.89. Therefore, Novo Nordisk A/S's PE Ratio without NRI for today is 42.61.

During the past 13 years, Novo Nordisk A/S's highest PE Ratio without NRI was 48.62. The lowest was 15.30. And the median was 25.28.


Novo Nordisk A/S Price-to-Owner-Earnings Historical Data

The historical data trend for Novo Nordisk A/S's Price-to-Owner-Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Novo Nordisk A/S Price-to-Owner-Earnings Chart

Novo Nordisk A/S Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Price-to-Owner-Earnings
Get a 7-Day Free Trial Premium Member Only Premium Member Only 21.60 23.13 37.33 35.62 36.17

Novo Nordisk A/S Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Price-to-Owner-Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 44.95 46.24 33.81 36.17 41.55

Competitive Comparison of Novo Nordisk A/S's Price-to-Owner-Earnings

For the Biotechnology subindustry, Novo Nordisk A/S's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Novo Nordisk A/S's Price-to-Owner-Earnings Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Novo Nordisk A/S's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where Novo Nordisk A/S's Price-to-Owner-Earnings falls into.



Novo Nordisk A/S Price-to-Owner-Earnings Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

Novo Nordisk A/S's Price-to-Owner-Earnings for today is calculated as

Price-to-Owner-Earnings=Share Price/Owner Earnings per Share (TTM)
=123.13/3.07
=40.11

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Novo Nordisk A/S  (NYSE:NVO) Price-to-Owner-Earnings Explanation

For how to get Owner Earnings per Share (TTM), please click.


Novo Nordisk A/S Price-to-Owner-Earnings Related Terms

Thank you for viewing the detailed overview of Novo Nordisk A/S's Price-to-Owner-Earnings provided by GuruFocus.com. Please click on the following links to see related term pages.


Novo Nordisk A/S (Novo Nordisk A/S) Business Description

Address
Novo Alle 1, Bagsvaerd, DNK, DK-2880
With roughly one third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (constituting roughly 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.